Our top pick for
Marchex Inc is an advertising agencies business based in the US. Marchex shares (MCHX) are listed on the NASDAQ and all prices are listed in US Dollars. Marchex employs 245 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.27|
|52-week range||$1.68 - $3.67|
|50-day moving average||$3.10|
|200-day moving average||$2.87|
|Wall St. target price||$4.38|
|Dividend yield||$0.5 (14.75%)|
|Earnings per share (TTM)||$-0.34|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||5.14%|
|1 month (2021-09-17)||2.83%|
|3 months (2021-07-16)||23.40%|
|6 months (2021-04-16)||12.76%|
|1 year (2020-10-16)||72.11%|
|2 years (2019-10-17)||2.83%|
|3 years (2018-10-17)||27.24%|
|5 years (2016-10-17)||27.24%|
Valuing Marchex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Marchex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Marchex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 million.
The EBITDA is a measure of a Marchex's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$53.5 million|
|Gross profit TTM||$30.3 million|
|Return on assets TTM||-13.82%|
|Return on equity TTM||-27.28%|
|Market capitalisation||$135.4 million|
TTM: trailing 12 months
There are currently 605,097 Marchex shares held short by investors – that's known as Marchex's "short interest". This figure is 3.4% up from 585,431 last month.
There are a few different ways that this level of interest in shorting Marchex shares can be evaluated.
Marchex's "short interest ratio" (SIR) is the quantity of Marchex shares currently shorted divided by the average quantity of Marchex shares traded daily (recently around 49884.336356142). Marchex's SIR currently stands at 12.13. In other words for every 100,000 Marchex shares traded daily on the market, roughly 12130 shares are currently held short.
However Marchex's short interest can also be evaluated against the total number of Marchex shares, or, against the total number of tradable Marchex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Marchex's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Marchex shares in existence, roughly 10 shares are currently held short) or 0.036% of the tradable shares (for every 100,000 tradable Marchex shares, roughly 36 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Marchex.
Find out more about how you can short Marchex stock.
We're not expecting Marchex to pay a dividend over the next 12 months.
Over the last 12 months, Marchex's shares have ranged in value from as little as $1.68 up to $3.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marchex's is 1.8952. This would suggest that Marchex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Marchex, Inc. operates as a call analytics company that helps businesses connect, drive, measure, and convert callers into customers. Its products include Marchex Call Analytics, an analytics platform for enterprises that depend on inbound phone calls to drive sales, appointments, and reservations; Marchex Speech Analytics that enable actionable insights for enterprise, mid-sized, and small businesses; Text Analytics and Communications, which enable businesses to send and receive text/SMS messages with customers; Call Monitoring; and Marchex Sales Edge that enable businesses to understand customer conversations in phone calls and text. The company also offers Marchex Omnichannel Analytics Cloud products, such as Marchex Search Analytics, a product for search marketers that drive phone calls from search campaigns; Marchex Display and Video Analytics, a product for marketers that buy digital display advertising; Marchex Site Analytics, a product for marketers that can drive phone calls from Websites; and Marchex Social Analytics, a product for marketers that buy social media advertising. In addition, it provides Marchex Audience Targeting that leverages call data to automatically build audience segments for display and social media platforms; and Marchex Call Marketplace, a mobile advertising network for businesses that depend on inbound phone calls to drive sales, as well as provides advertisers ad placements across various mobile and online media sources to deliver qualified calls to their businesses. In addition, it provides Local Leads platform, a service advertising solution for small business resellers, such as Yellow Pages providers and vertical marketing service providers to sell call advertising, search marketing, and other lead generation products through their existing sales channels to small business advertisers. Marchex, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.